MNK Inhibitor AUM001 in Combination With Either Pembrolizumab or Irinotecan to Treat Metastatic Colorectal Cancer

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated July 9, 2024 (before its estimated September 30, 2024 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since Jul 2024); last known: Recruiting
  2. Re-verified, no change to tracked fieldsv5
  3. Primary completion date: Aug 15, 2023 to Sep 30, 2024
    • Study sites: 1 to 5
    • Interventions: AUM001 (Drug), Irinotecan (Drug), Pembrolizumab (Drug) to Irinotecan (Drug), Pembrolizumab (Drug), Tinodasertib (Drug)
    • Study description revised
    v4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 15, 2022 to Apr 14, 2023
    • Study sites: 0 to 1
    v3
  5. Collaborators expanded, about 5 wordsv2
  6. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study is a 2-part study of Tinodasertib alone or in combination with Pembrolizumab/Irinotecan in patients with CRC.
Trial Details
NCT Number NCT05462236
Lead Sponsor AUM Biosciences Pte Ltd
Collaborators: Merck Sharp & Dohme LLC
Conditions
(from sponsor)		 Metastatic Colorectal Cancer
Related terms Colorectal Neoplasms
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov